Dendritic cell (DC)-based immunomodulatory approaches showed initial success in both animal models (22) and clinical trials in ACPA positive RA patients genetically predisposed to disease by possessing human leukocyte antigen-shared epitope (HLA-SE) risk alleles (27). Here, PRTN3 is linked to rheumatoid arthritis.